
|Articles|July 1, 2004
ISTA seeks bromfenac OK; gets nod for injected hyaluronidase
Irvine, CA-ISTA Pharmaceuticals Inc. is seeking FDA approval of its bromfenac sodium ophthalmic solution 0.1% (Xibrom) for the treatment of ocular inflammation following cataract surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Retina experts reflect on how OCT transformed patient care
2
AAO 2025: The ASPIRE phase 2B trial of UBX1325 head-to-head against aflibercept
3
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
4
Redefining glaucoma care: Where innovation meets clinical insight
5



















































.png)


